New strategies that can induce anti-tumor immune responses with which anti-PD-1/L1 therapy can synergize, reverse the immune-deficient tumor microenvironment, and which can re-establish tumor sensitivity to systemic anti-PD-1/L1 therapy are therefore needed. The gene discussed is PDCD1; the disease is neoplasm.